Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protana: IgE Reduction for Food Anaphylaxis
NCT03964051Phase 4Terminated
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in food allergy. Primary endpoint: Change in food challenge threshold at 18 weeks. Started Jul 2019; status: terminated.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT03964051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964051.